Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative panitumumab + FOLFIRI for potentially resectable wild-type RAS colorectal liver metastases
2012-000265-20Phase 2Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM), sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoint: Objective response rate. Started May 2012; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on 2012-000265-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000265-20.